CG Oncology (CGON) Fundamentals 2026 — Revenue Analysis | SniperIQ
CG Oncology (CGON) is a US-listed Healthcare company in Biotechnology with a market capitalization of $6.2B, trading at $70.37 on the NASDAQ. This SniperIQ fundamentals page covers CG Oncology's valuation, profitability (net margin -3682.6%), revenue ($4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CG Oncology's market cap?
CG Oncology (CGON) has a market capitalization of approximately $6.2B, trading at $70.37 on the NASDAQ. Market cap moves with the live share price.
What is CG Oncology's P/E ratio?
CG Oncology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CG Oncology?
CG Oncology runs a net profit margin of -3682.6%, a gross margin of -664.8%, and an operating margin of -4239.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CG Oncology generate?
CG Oncology reported revenue of $4M for fiscal year 2025, with net income of -
Does CG Oncology pay a dividend?
CG Oncology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CG Oncology financially healthy?
CG Oncology carries a debt-to-equity ratio of 0.01x and a current ratio of 31.30x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CG Oncology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CG Oncology (CGON) the key facts are: market cap $6.2B, revenue $4M, 52-week range 23.65-77. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track CG Oncology's full fundamentals live
Get CG Oncology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.